左氧氟沙星联合头孢哌酮舒巴坦与莫西沙星治疗慢性支气管炎并肺炎的疗效-成本分析

Effect-Cost Analysis in Treating Chronic Bronchitis Complicated by Pneumonia with Levofloxacin in Combination of Cefoperazone Sulbactam versus Moxifloxacin

目的对左氧氟沙星联合头孢哌酮舒巴坦与莫西沙星治疗慢支(慢性支气管炎)并肺炎进行疗效-成本分析。方法选择慢支并肺炎患者189例,随机分成左氧氟沙星联合头孢哌酮舒巴坦治疗组96例,莫西沙星对照组93例,观察两组疗效和不良反应,并运用药物经济学的成本-效果分析方法进行药物经济学评价。结果治疗组总有效率为92%,对照组为75%,治疗组经济性更佳。结论在治疗慢支并肺炎中,左氧氟沙星联合头孢哌酮舒巴坦效价比高,是较佳的治疗方案。

Objective To carry out effect-cost analysis in treating chronic bronchitis complicated by pneumonia with levofloxacin in combination of cefoperazone and sulbactam versus moxifloxacin.Method Selected 189 cases of chronic bronchitis complicated by pneumonia patients,randomly divided them into a treatment group of 96 cases treated with levofloxacin in combination of cefoperazone and sulbactam and a comparison group of 93 cases treated with moxifloxacin,observed the treatment effects and adverse reaction,and used cost-effect analytical method within pharmacoeconomics to perform pharmacoeconomics evaluation.Results The total effective rate of the treatment group was 92%while that of the comparison group was 75%,with the treatment group having better economy.Conclusion In treating chronic bronchitis complicated by pneumonia,the effect-price ratio of treatment with levofloxacin in combination of cefoperazone and sulbactam is higher,and therefore it is a better treatment plan.